-
Mashup Score: 2
While RFK Jr. has been a vocal critic of pharma, industry executives are shrugging off potential impact
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2A guide to the health systems and companies driving adoption - 2 day(s) ago
STAT has launched a Generative AI Tracker to keep tabs on the new ways health care systems are using the technology.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
Stay on top of all the health care leaders and tech companies investing in generative AI with STAT's tracker. https://t.co/bfXsVUN1IM
-
-
Mashup Score: 3Why the crowded market for ambient AI medical scribes might be ripe for consolidation - 2 day(s) ago
Even as more health systems adopt ambient scribes, the technology providers might find it harder to differentiate themselves, analysts say.
Source: www.statnews.comCategories: General Medicine News, General NewsTweet-
The number of health systems looking to contract with an AI scribe company is growing. But analysts see signs of consolidation where only the big players will survive. https://t.co/skbSArsCpC
-
-
Mashup Score: 3Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease - 2 day(s) ago
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a “major new path” of cardiovascular therapy.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
Two drugs look promising for a common genetic risk factor for heart disease https://t.co/RdRIDqEzUx
-
-
Mashup Score: 1Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast - 2 day(s) ago
.@nes047 and @NathanielEDavid formed Jupiter Bioventures to quickly test out, and if necessary discard, ideas in biotech.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast https://t.co/pBcEZoXGgc
-
-
Mashup Score: 0Syndax wins U.S. approval for leukemia treatment - 2 day(s) ago
The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
The FDA approved a new drug developed by Syndax Pharmaceuticals to treat patients with a genetically defined form of advanced leukemia. https://t.co/Y4cQTcpamc
-
-
Mashup Score: 0A win for Apellis, a setback for Astellas - 2 day(s) ago
The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less frequent injections and include data showing the effect of the drug over two years.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less frequent injections and include data showing the effect of the drug over two years. https://t.co/mslPfluG3w
-
-
Mashup Score: 6
Trump’s HHS pick could reshape public health agencies and usher in a new era for vaccines, food, and medicines.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
RT @GideonGil: What to know about RFK Jr.’s views on food, vaccines, abortion, and the FDA https://t.co/Y6587qanL9 via @statnews
-
-
Mashup Score: 4Pharmalittle: We're reading about a key Merck drug trial, cheap Wegovy in China, and more - 2 day(s) ago
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as when given intravenously
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as when given intravenously https://t.co/j63vNGmfMx
-
-
Mashup Score: 1Why the crowded market for ambient AI medical scribes might be ripe for consolidation - 2 day(s) ago
Even as more health systems adopt ambient scribes, the technology providers might find it harder to differentiate themselves, analysts say.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
Even as more health systems adopt ambient scribes, the technology providers might find it harder to differentiate themselves, analysts say. https://t.co/1K7vpKxRlk
-
While RFK Jr. has been a vocal critic of pharma, industry executives are shrugging off potential impact https://t.co/e0KsBPScNl